Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respiratory Research 2022, 9: e001254. PMID: 35882424, PMCID: PMC9329732, DOI: 10.1136/bmjresp-2022-001254.Peer-Reviewed Original ResearchMeSH KeywordsCommunicable DiseasesCOVID-19HumansPandemicsProspective StudiesQuality of LifeSARS-CoV-2Treatment OutcomeConceptsLung functionRespiratory infectionsLocal institutional review board approvalFibrotic pulmonary sarcoidosisInstitutional review board approvalNon-infected patientsInterstitial lung diseaseRespiratory viral illnessReview board approvalViral infectious diseasesImpact of infectionPulmonary sarcoidosisViral illnessClinical courseInfectious eventsStudy entryStudy cohortPoor outcomeProspective studyLung diseaseLong-term impactLife measuresSarcoidosisHigh riskGeneral population